Pepex Biomedical’s mission is to become the leading technology source, prime supplier, and marketer of enzymatic biosensors for consumer medical devices and hospital diagnostic use.

Renowned scientist Professor Adam Heller (inventor of the lithium thionyl chloride battery) developed technology that today is well known as “wired enzyme2” and under E. Heller & Company formed TheraSense, LLC to explore potential medical applications for his new discovery. Early in this process Dr. Heller was approached by Dr. Eric Peper, a respected heart surgeon wishing to explore the use of “wired enzyme” in conjunction with his own novel concepts.

Ultimately Pepex Biomedical was formed from these concepts and under rights granted by E. Heller & Company, began a five-year joint development and technology sharing agreement with TheraSense. In 2004, Subsequently TheraSense was acquired by Abbott Laboratories and is remains operatinged today as Abbott Diabetes Care, marketing their FreeStyle® family of glucose monitoring systems. Subsequently, Pepex continued its R&D efforts and has amassed an extensive IP portfolio of over 300 global patents that protect our proprietary manufacturing process and unique biosensor design capable of detecting 800 unique biomarkers including COVID-19, Sepsis, HIV, Ebola, Hepatitis and other life-altering antigens.

For years the biosensor industry has relied on what is referred to as “strip based” or “planar” sensors. These sensors are used in consumer products for self-test kits for everything from pregnancy to diabetes monitors and in the clinical environment in a variety of blood tests for patient monitoring and diagnosis. Over time a host of new products and product improvements have boosted the strip sensor market particularly in the self-test monitoring of blood glucose for diabetics.

However, future advancements in this field are limited due to the inherent limitations of the current test strip manufacturing process and the advanced age of printed sensor technology which is now over 25 years old. This is because the current planar technology, or “flat sensors,” use a print- based strip composed of a layered matrix of paper, adhesives, chemistry, and conductors cut from sheets. The flat sensor ultimately produced by this process is painful and difficult to implant into live tissue. In addition, the manufacturing process is complex and susceptible to error.

By comparison Pepex’s advanced sensors and novel manufacturing processes enables the development of an easy to use devices that sets Pepex apart from the rest of the industry. Our exclusive production process provides significant enhancements to precision through the science of nanotechnology, adding meaningful benefits for high volume output while minimizing cost issues in all of our products. Prototype research has already been completed for both electrochemistry and engineering using AJP, each of which The minimal sample size promotes virtually pain free testing. The technology is adaptable to virtually all diabetic and disposable enzymatic sensor markets, to the support the “micro invasive” trend in monitoring systems, and to the rapidly emerging demand for indwelling micro sensors.

Pepex first identified, then developed methods to specifically resolve a host of industry problems, and in the process created a whole new standard of care in patient monitoring previously unobtainable. Our technology allows for significantly greater miniaturization (demanded by the industry), dramatically improved accuracy and reliability (required in clinical care and treatment), all at a substantial cost reduction in manufacturing (decreasing cost and improving profitability).

Pepex Announces New Rapid Covid-19 Point Of Care Test